Literature DB >> 26890120

Synthesis and anti-cancer activity evaluation of 5-(2-carboxyethenyl)-isatin derivatives.

Yu-Ou Teng1, Hong-Ye Zhao1, Jing Wang1, Huan Liu1, Mei-Le Gao1, Yao Zhou1, Kai-Lin Han1, Zhen-Chuan Fan2, Yong-Min Zhang3, Hua Sun1, Peng Yu4.   

Abstract

A series of novel di- or trisubstituted isatin derivatives were designed and synthesized in 5-6 steps in 25-45% overall yields. Their structures were confirmed by 1H NMR and 13C NMR as well as LC-MS. The anticancer activity of the fourty-three new isatin derivatives against human T lymphocyte cells Jurkat was evaluated by MTT assay in vitro. SAR study suggested that the combination of 1-benzyl and 5-[trans-2-(methoxycarbonyl)ethen-1-yl] substitution greatly enhanced their cytotoxic activity. Among them, compound 2h was shown to have a significant cytotoxic activity with an IC50 value of 0.03 μM, more than 330-fold higher than that of it's mother molecule isatin. Investigation of the cell morphology changes and annexin-V/PI staining study demonstrated that compound 2h inhibited the proliferation of Jurkat cells by inducing apoptosis. Since compound 2h induced the dissipation of mitochondrial membrane potential and the activation of caspase-3, it was obvious that compound 2h inhibited the proliferation of Jurkat cells through the mitochondrial apoptotic pathway. Other than this, compound 2h exerted inhibition effect to many other tumor cells and only showed weak cytotoxic to human normal cells suggesting that compound 2h possessed a broad range of anticancer spectrum and high safety to normal cells.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-tumor agents; Apoptosis; Isatin derivatives; Jurkat cells; Proliferation

Mesh:

Substances:

Year:  2016        PMID: 26890120     DOI: 10.1016/j.ejmech.2015.12.050

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids.

Authors:  Rita Meleddu; Vilma Petrikaite; Simona Distinto; Antonella Arridu; Rossella Angius; Lorenzo Serusi; Laura Škarnulytė; Ugnė Endriulaitytė; Miglė Paškevičiu Tė; Filippo Cottiglia; Marco Gaspari; Domenico Taverna; Serenella Deplano; Benedetta Fois; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-12-18       Impact factor: 4.345

Review 2.  A Mini Review on Isatin, an Anticancer Scaffold with Potential Activities against Neglected Tropical Diseases (NTDs).

Authors:  Shefali Chowdhary; Amandeep Arora; Vipan Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

3.  Azide-Alkyne Cycloaddition En Route to 1H-1,2,3-Triazole-Tethered Isatin-Ferrocene, Ferrocenylmethoxy-Isatin, and Isatin-Ferrocenylchalcone Conjugates: Synthesis and Antiproliferative Evaluation.

Authors:  Amandeep Singh; Sourav Taru Saha; Shanen Perumal; Mandeep Kaur; Vipan Kumar
Journal:  ACS Omega       Date:  2018-01-30

4.  Synthesis and Preliminary Antimicrobial Analysis of Isatin-Ferrocene and Isatin-Ferrocenyl Chalcone Conjugates.

Authors:  Amandeep Singh; Grant Fong; Jenny Liu; Yun-Hsuan Wu; Kevin Chang; William Park; Jihwan Kim; Christina Tam; Luisa W Cheng; Kirkwood M Land; Vipan Kumar
Journal:  ACS Omega       Date:  2018-05-30

5.  Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation.

Authors:  Qian Zhang; Yuou Teng; Yuan Yuan; Tingting Ruan; Qi Wang; Xing Gao; Yao Zhou; Kailin Han; Peng Yu; Kui Lu
Journal:  Eur J Med Chem       Date:  2018-07-25       Impact factor: 6.514

6.  Synthesis and Antiproliferatory Activities Evaluation of Multi-Substituted Isatin Derivatives.

Authors:  Ying Ding; Lianbo Zhao; Ying Fu; Lei Hao; Yupeng Fu; Yuan Yuan; Peng Yu; Yuou Teng
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

Review 7.  Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery.

Authors:  Rameshwar S Cheke; Vaishali M Patil; Sandip D Firke; Jaya P Ambhore; Iqrar A Ansari; Harun M Patel; Sachin D Shinde; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan; Mohd Adnan; Adel Kadri; Mejdi Snoussi
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.